Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

StockNews.com

Exclusive-Short AstraZeneca shelf life complicates COVID vaccine rollout to world's poorest

Reuters

Germany and Switzerland set to ease restrictions – as it happened

This blog is now closed.

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Short AstraZeneca Shelf Life Complicates COVID Vaccine Rollout to World’s Poorest

The relatively short shelf life of AstraZeneca Plc's COVID-19 vaccine is complicating the rollout to the world's poorest nations, according to officials and internal World Health Organization documents reviewed by Reuters. It is the latest headache to plague the COVAX vaccine-sharing project, co-led by the WHO and aimed at getting…

Asharq Al-Awsat

Why Are AstraZeneca Shares Trading Higher Today

Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed

Benzinga

Vaccinated people less likely to get long Covid than unvaccinated, new study shows

Review finds those who have received two doses of Pfizer/BioNTech, AstraZeneca or Moderna vaccine, or one dose of single-shot J&J vaccine, half as likely to develop long Covid symptoms

The Independent UK

UK pay growth lags behind inflation; company insolvencies rise – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca Stock Ranked No. 1 In Group; Recently Reported Record Sales, Strong Outlook

AstraZeneca recently reported record sales, and a bullish outlook. Its stock continues to idle though amid overall market weakness.

Investors Business Daily

Software firm used by Coca-Cola, the UK Parliament and AstraZeneca acquired

Its clients also include Manchester Airports Group, Highways England and Unilever

Birmingham Post

How An AstraZeneca Rivalry Led Seagen Stock To Crumble Despite A Sales Beat

Seagen offered a disappointing outlook for 2022 as AstraZeneca pressures its new breast cancer drug, leading SGEN stock to dive on Thursday.

Investors Business Daily

Astra warns on falling Covid treatment sales after record year

London (AFP) - British Covid vaccine maker AstraZeneca on Thursday warned that coronavirus product sales and profit margins would drop this year as the pandemic recedes and after record-high group revenue in 2021.

AFP

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

AstraZeneca: Q4 Earnings Insights

AstraZeneca (NASDAQ:AZN) reported its Q4 earnings results on Thursday, February 10, 2022 at 02:15 AM. Here's what investors need to know about the announcement.

Benzinga

AstraZeneca warns on falling Covid treatment sales

London (AFP) - British Covid vaccine maker AstraZeneca on Thursday warned that coronavirus product sales and profit margins would drop this year as the pandemic recedes.

AFP

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21

AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 63% Y/Y to $12.0

The Guardian - UK

AstraZeneca forecasts higher 2022 sales after record revenues

Drugmaker’s total revenues increased by 41% last year with help from $4bn Covid jab income

Wales Online

AstraZeneca Covid jab sales hit £3bn

The manufacturer said it expected revenues on coronavirus products to drop in future

The Independent UK

AstraZeneca sees $4B in COVID vaccine sales as revenue soars

AstraZeneca has recorded a big jump in revenue as it begins to take a profit from its coronavirus vaccine for the first time

Get all your
news in one place.

100’s of premium titles.
One news app.

AFP

Covid vaccine maker AstraZeneca says 2021 profit dives

London (AFP) - British Covid vaccine maker AstraZeneca said Thursday that net profit collapsed last year, hit by the vast takeover of US biotech firm Alexion and other charges, despite surging revenues.

Birmingham Post

AstraZeneca Covid jab sales rose to £3bn in 2021

The drugs giant swung to a bottom line pre-tax loss of £196m for last year

The Guardian - UK

Wall Street drops as interest rate rises loom after US inflation hits 7.5% – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - AU

Covid news: Spain drops mandatory use of face masks outdoors; UK reports another 66,638 daily cases – as it happened

Face coverings still required in indoor public spaces in Spain; UK records 66,638 daily infections and 206 Covid-linked deaths

ABC News

TGA provisionally approves AstraZeneca COVID booster vaccine for Australians aged 18 years and older

Australia's medical regulator gives its first green light to the AstraZeneca booster shot for people above the age of 18.

The Independent UK

How effective are the Pfizer, AstraZeneca and Moderna vaccines against Omicron?

Booster jabs provide up to 70 per cent protection, study finds

AAP

AstraZeneca booster provisionally approved

The AstraZeneca booster shot has been provisionally approved by the Therapeutic Goods Administration for people aged 18 and over.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.